Abacus Planning Group Inc. Sells 57 Shares of Eli Lilly and Company $LLY

Abacus Planning Group Inc. cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,431 shares of the company’s stock after selling 57 shares during the quarter. Abacus Planning Group Inc.’s holdings in Eli Lilly and Company were worth $1,895,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the company. WestEnd Advisors LLC boosted its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, TD Capital Management LLC increased its position in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LLY shares. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Morgan Stanley reissued an “overweight” rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Finally, Berenberg Bank reiterated a “hold” rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $939.61.

Insider Activity

In other Eli Lilly and Company news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 0.6%

NYSE:LLY opened at $820.69 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The stock’s fifty day simple moving average is $734.03 and its 200-day simple moving average is $766.34. The firm has a market capitalization of $776.75 billion, a P/E ratio of 53.64, a P/E/G ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 earnings per share. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.